

## Press Release

18 June 2024 13:45:00 CEST

# 2CUREX APPOINTS OLE THASTRUP AS NEW CEO

2cureX AB (publ), a company pioneering the use of 3D tumoroids for drug sensitivity prediction in cancer patients, is pleased to announce the appointment of its Founder, Ole Thastrup, as the new CEO.

Tonni Bülow-Nielsen, Chairman of the Board, expressed his enthusiasm, stating:

“We are delighted to have Ole assume the CEO role during this pivotal phase in 2cureX’s development. Additionally, I extend my gratitude to our CFO Kenneth G. Johansen for taking the responsibility as Acting CEO in an interim period.”

Ole Thastrup, the newly appointed CEO of 2cureX, remarked:

“Yesterday, we unveiled significant changes to the 2cureX Group ([Press Releases & News | 2cureX](#)).

The implementation of these changes, along with the associated investments, will expedite the adoption of functional drug sensitivity testing in the design of individualized cancer treatments. I look forward assisting in this effort alongside our skilled team and dedicated investors.”

For more information about 2cureX:

---

Ole Thastrup, Vice-Chairman & CEO

E-mail: [ot@2curex.com](mailto:ot@2curex.com)

Telephone: +45 2211 5399

[www.2curex.com](http://www.2curex.com)

## About 2cureX

---

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit [www.2cureX.com](http://www.2cureX.com)

Certified Adviser: Redeye AB

*This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-06-18 13:45 CEST.*

## Attachments

---

### 2CUREX APPOINTS OLE THASTRUP AS NEW CEO